<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04255771</url>
  </required_header>
  <id_info>
    <org_study_id>ShandongPH Urology</org_study_id>
    <nct_id>NCT04255771</nct_id>
  </id_info>
  <brief_title>A Study of Postoperative Adjuvant Chemotherapy for Upper Urinary Urothelial Carcinoma With Lymphovascular Invasion</brief_title>
  <official_title>A Prospective Randomized Controlled Trial for Postoperative Adjuvant Chemotherapy for pTanyN0M0 Upper Urinary Urothelial Carcinoma With Lymphovascular Invasion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Qinghua Xia,Prof</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shandong Provincial Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This project is to explore the effect of adjuvant chemotherapy on total tumor survival time,
      progression-free survival time, and recurrence-free survival time in patients with pTanyN0M0
      upper urinary urothelial carcinoma with lymphatic vascular invasion (LVI) through a
      prospective case-control study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This project is to explore the effect of adjuvant chemotherapy on total tumor survival time,
      progression-free survival time, and recurrence-free survival time in patients with pTanyN0M0
      upper urinary urothelial carcinoma with lymphatic vascular invasion (LVI) through a
      prospective case-control study. Therapeutic value of adjuvant chemotherapy for LVI(+)
      patients with pT1N0M0, pT2N0M0, and pT3-4N0M0 upper urinary urothelial carcinoma,
      respectively.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 1, 2020</start_date>
  <completion_date type="Anticipated">June 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total tumor survival time</measure>
    <time_frame>3 years</time_frame>
    <description>Effect of postoperative adjuvant chemotherapy on total tumor survival time</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>progression-free survival time</measure>
    <time_frame>3 years</time_frame>
    <description>Effect of postoperative adjuvant chemotherapy on progression-free survival time</description>
  </secondary_outcome>
  <other_outcome>
    <measure>relapse-free survival time</measure>
    <time_frame>3 years</time_frame>
    <description>Effect of postoperative adjuvant chemotherapy on relapse-free survival time</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Chemotherapy Effect</condition>
  <arm_group>
    <arm_group_label>Effect of adjuvant chemotherapy on pTanyN0M0 UTUC with LVI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This project is to explore the effect of adjuvant chemotherapy on total tumor survival time, progression-free survival time, and recurrence-free survival time in patients with pTanyN0M0 upper urinary urothelial carcinoma with lymphatic vascular invasion (LVI) through a prospective case-control study. Therapeutic value of adjuvant chemotherapy for LVI(+) patients with pT1N0M0, pT2N0M0, and pT3-4N0M0 upper urinary urothelial carcinoma, respectively.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Effect of placebo on pTanyN0M0 UTUC with lymphatic invasion</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>As a control, this clinical trial also set up a placebo control group. The effect of adjuvant chemotherapy was obtained by random grouping and comparing the effects of patients in the experimental group and the control group.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>Standard GC (gemcitabine and cisplatin) regimen: gemcitabine 1000-1200mg/m2 intravenous infusion on days 1 and 8, cisplatin 70mg/m2 on the second day of intravenous infusion, every 3 weeks (21-day regimen) is a cycle, A total of 3 cycles.</description>
    <arm_group_label>Effect of adjuvant chemotherapy on pTanyN0M0 UTUC with LVI</arm_group_label>
    <other_name>Cisplatin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebos</intervention_name>
    <description>Use a placebo as a comparison</description>
    <arm_group_label>Effect of placebo on pTanyN0M0 UTUC with lymphatic invasion</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Aged 20-85 years;

          2. ECOG score 0-1 points;

          3. Patients with UTUC, undergoing radical nephrectomy, pathological staging For
             pTanyN0M0;

          4. Patients voluntarily signed informed consent.

        Exclusion Criteria:

          1. Obvious cardiopulmonary dysfunction, serious diabetes and other chronic diseases;

          2. Obvious chemotherapy contraindications;

          3. Patients have a history of other organ malignancies;

          4. Combined with tumors of other sites.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Qinghua Xia, Prof</last_name>
    <role>Study Director</role>
    <affiliation>Shandong Provincial Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Shandong Provincial Hospital</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <zip>250021</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Qinghua Xia,Prof, professor</last_name>
      <phone>0086053168773146</phone>
      <phone_ext>3147</phone_ext>
      <email>phsandi@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>January 21, 2020</study_first_submitted>
  <study_first_submitted_qc>February 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 5, 2020</study_first_posted>
  <last_update_submitted>February 15, 2020</last_update_submitted>
  <last_update_submitted_qc>February 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Shandong Provincial Hospital</investigator_affiliation>
    <investigator_full_name>Qinghua Xia,Prof</investigator_full_name>
    <investigator_title>Deputy Director of Urology, Shandong Provincial Hospital</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Transitional Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

